Proliferative Activity in Libyan Breast Cancer with Comparison to European and Central African Patients
Table 4
Proliferative indices of Libya, Nigeria, and Finland in whole patient materials and in subgroups.
Libya (130)
Finland° (364)
Nigeria* (300)
value
Libya versus Finland
Libya versus Nigeria
SMI
Whole material
32.1 (21.0)
13.8 (17.8)
42.6 (27.5)
<0.0001
<0.0001
MAI
27.3 (18.5)
10.7 (16.5)
30.5 (25.1)
<0.0001
0.192
SMI
LN+
34.8 (21.8)
17.8 (19.3)
45.4 (27.6)
<0.0001
0.001
LN−
21.5 (13.0)
11.6 (16.5)
32.6 (25.1)
0.003
0.032
Postmenopause
37.7 (25.7)
11.2 (13.4)
44.9 (26.6)
<0.0001
0.134
Premenopause
28.5 (16.6)
19.6 (29.0)
41.9 (27.8)
0.014
<0.0001
Grade 1
14.9 (9.2)
NA
11.8 (11.4)
NA
0.427
Grade 2
32.1 (19.3)
NA
31.7 (16.5)
NA
0.880
Grade 3
35.4 (23.3)
NA
61.9 (24.5)
NA
<0.0001
Stage 1
15.7 (9.3)
NA
32.6 (25.1)
NA
0.108
Stage 2
25.0 (14.5)
NA
41.9 (28.3)
NA
<0.0001
Stage 3
36.1 (22.2)
NA
48.9 (28.8)
NA
0.003
Stage 4
41.3 (21.0)
NA
44.3 (24.4)
NA
0.650
MAI
LN+
29.0 (17.9)
13.4 (17.4)
32.7 (25.6)
<0.0001
0.184
LN−
20.6 (19.7)
9.2 (15.8)
22.6 (21.2)
0.001
0.675
Postmenopause
32.7 (19.8)
8.8 (11.9)
33.8 (24.9)
<0.0001
0.793
Premenopause
23.9 (17.0)
14.9 (23.2)
29.4 (22.1)
0.004
0.044
Grade 1
12.8 (9.6)
NA
4.2 (3.8)
NA
<0.0001
Grade 2
25.4 (17.1)
NA
16.8 (10.1)
NA
<0.0001
Grade 3
32.7 (20.0)
NA
50.9 (21.9)
NA
<0.0001
Stage 1
15.7 (9.3)
NA
22.6 (21.2)
NA
0.434
Stage 2
25.0 (14.5)
NA
28.3 (24.4)
NA
0.416
Stage 3
36.1 (22.2)
NA
36.6 (26.8)
NA
0.901
Stage 4
41.3 (21.0)
NA
31.9 (24.7)
NA
0.162
Data on Nigeria and Finland are basically the same as those published in the study of *Ikpatt et al. [6, 7] and °Kronqvist et al. [9]. Significance is estimated by one-way ANOVA test.
